Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by the decrease of platelet count. In recent years, the pathogenesis, diagnosis and treatments of adult ITP have achieved significant progress. In particular, with wide clinical applications of rituximab, thrombopoietin (TPO) and TPO receptor agonist (TPORA) in ITP, the second-line treatment options have no longer limited to splenectomy. This article mainly discusses the second-line treatment options of adult ITP after first-line treatments failure, in order to provide individualized treatments. Key words: Thrombocytopenia; Adult; Splenectomy; Rituximab; Thrombopoietin; Thrombopoietin receptor agonist
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.